Wahrnehmung der Schutzimpfung gegen die Neue Grippe H1N1 von Patienten mit Morbus Crohn oder Colitis ulcerosa

Teich, Niels; Schmidt, Carsten; Stallmach, Andreas; Klugmann, Tobias; Vieth, M; Baumgart, DC; Sturm, Andreas; Felten, G; Hüppe, D; Emmrich, Joerg; Böcker, Ulrich; Bästlein, EC; Ehehalt, Robert; Krummenerl, Thomas; Bachmann, Oliver; Kruis, Wolfgang; Mroß, Michael; Herrlinger, K; Helwig, Ulf; Büning, Jürgen; Aschenbeck, Jens; Siegmund, Britta; Preiß, J; Maul, Jochen; Drossel, R; Schiefke, I; Reinshagen, Max; Heidemann, Jan; Lügering, Andreas; Rehbehn, Kai-Uwe; Pfeiffer, A.; Jessen, P; Schreiber, Stefan; Rosezin, B; Dignaß, Axel; Böhm, Stephan; Bokemeyer, B.

doi:10.1055/s-0031-1275829

Cited by 3 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[38] The possibility that immune mediated diseases could flare after a vaccination cannot theoretically be excluded and, indeed, a case report has been published. [39] However a recent observational study[40] was conducted on 575 IBD patients during the pandemic vaccine campaign, to evaluate the safety of both adjuvanted and not adjuvanted vaccines, containing different virus antigen doses.…”

Section: Discussionmentioning

confidence: 99%

Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants

Andrisani

Frasca

Romero

et al. 2013

Journal of Crohn's and Colitis

View full text Add to dashboard Cite

Background and Aims Our first objective was to evaluate the immune response to the adjuvanted 2009 A/H1N1 pandemic (pH1N1) vaccine in inflammatory bowel disease (IBD) patients treated with anti-TNF-α alone or combined with immunosuppressants (IS). Second and third aims were the safety of pH1N1 vaccine and the effects on IBD clinical activity. Methods 36 patients with Crohn's disease (CD) and 26 with ulcerative colitis (UC) and thirty-one healthy control subjects (HC) were enrolled. 47 patients were on anti TNF-α maintenance monotherapy and 15 on anti TNF-α combined with IS. Sera were collected at baseline (T0) and 4 weeks after the vaccination (T1) for antibody determination by hemagglutination inhibition (HAI Disease activity was monitored at T0 and T1. Results Seroprotective titers (≥ 1: 40) in patients were comparable to HC. Seroconvertion rate (≥ 4 fold increase in HAI titer) was lower than HC in IBD patients (p=0,009), either on anti TNF-α monotherapy (p=0,034) or combined with IS (p=0,011). Geometric mean titer (GMT) of antibodies at T1 was significantly lower in patients on combined therapy versus those on monotherapy (p=0,0017) and versus HC (p=0,011). The factor increase of GMT at T1 versus T0 was significantly lower in IBD patients versus HC (p=0,042), and in those on combined immunosuppression, both versus monotherapy (p=0,0048) and HC (p=0,0015). None of the patients experienced a disease flare. Conclusion Our study has shown a suboptimal response to pH1N1 vaccine in IBD patients on therapy with anti TNF-α and IS compared to those on anti-TNF-α monotherapy and HC.

show abstract

Section: Discussionmentioning

confidence: 99%

Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants

Andrisani

Frasca

Romero

et al. 2013

Journal of Crohn's and Colitis

View full text Add to dashboard Cite

show abstract

Kompetenznetz Darmerkrankungen

Schreiber

Hartmann

Kruis

et al. 2016

Bundesgesundheitsbl.

View full text Add to dashboard Cite

The Inflammatory Bowel Disease Competence Network is a network of more than 500 physicians and scientists from university clinics, hospitals and gastroenterology practices. The focus extends from the two major forms of inflammatory bowel diseases, Crohn's disease and ulcerative colitis, into other chronic inflammatory conditions affecting the intestine, including coeliac disease and microscopic colitis. The network translates basic science discoveries (in particular in the molecular epidemiology research) into innovative diagnostics and therapy. Through its strong networking structures it supports a continuous process to improve quality and standardisation in patient care that is implemented in close interaction with European networks addressing this disease group.Optimisation of patient care based on scientifically proven evidence is a main focus of the network. Therefore, it supports and coordinates translational research and infrastructure projects that investigate aetiology, improvement of diagnostic methods, and development of new or improved use of established therapies. Members participate in various training projects, thus ensuring the rapid transfer of research results into clinical practice.The competence network cooperates with the main patient organisations to engage patients in all levels of activities. The network and the patient organisations have interest in promoting public awareness about the disease entities, because their importance and burden is underestimated in non-specialised medical fields and among the general public.

show abstract

Prävention von Infektionen und infektiösen Komplikationen bei chronisch-entzündlichen Darmerkrankungen

2019

View full text Add to dashboard Cite

Wahrnehmung der Schutzimpfung gegen die Neue Grippe H1N1 von Patienten mit Morbus Crohn oder Colitis ulcerosa

Abstract: Only a minority of patients with Crohn's disease or ulcerative colitis had adhered to the official recommendation concerning vaccination against H1N1. In order to reach higher acceptance, further vaccination campaigns must focus on the safety of the recommended vaccine.

Cited by 3 publications

References 2 publications

Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants

Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants

Kompetenznetz Darmerkrankungen

Prävention von Infektionen und infektiösen Komplikationen bei chronisch-entzündlichen Darmerkrankungen

Contact Info

Product

Resources

About